Whether probiotics can replace antibiotic growth promoters (AGPs) depends on the function being replaced. In some broiler experiments, particular preparations produced better feed conversion than the AGP comparator. That does not mean every probiotic gives the same production outcomes across diets, ages and health settings, or can replace disease treatment. This review focuses on broiler trials and separates performance, community measurements and material identity to explain how a conditional research finding can support a specific claim for evaluation.

Define the endpoint in a probiotic–AGP comparison
Growth promotion is commonly evaluated through weight gain, feed intake and feed efficiency. A probiotic assessment needs a similarly defined primary endpoint, an unsupplemented control and an appropriate comparator. More of a bacterial genus does not establish better feed efficiency. Lower FCR should also be read alongside gain, intake and health records from the same period.
Feed conversion ratio is feed input relative to weight gain; lower is generally better when definitions are comparable. It is distinct from growth rate, final weight and survival. Statistical comparisons must respect treatment allocation. In group feeding, the pen or cage is often the relevant independent dietary replicate rather than each bird.
What did a 35-day trial show?
Selim and colleagues studied 320 male Arbor Acres plus broilers in five groups, with eight replicates of eight birds per group over 35 days. Treatments included a basal diet, avilamycin comparator, an algal combination, rosemary essential oil and a mixed probiotic. The mixed material contained Bacillus, Enterococcus, Lactobacillus and yeast. Its effect belongs to the tested combination, not to one component considered alone.[1]
Overall FCR in the source table was 1.71 for the basal diet,1.64 for the AGP,1.55 for the algal combination,1.61 for the oil and 1.56 for the mixed probiotic. The chart retains all five groups. The probiotic and AGP groups share no statistical letter, supporting a difference in that experiment. The oil and AGP groups share a letter, so a lower oil-group mean alone does not establish a significant pairwise difference.[1]
Figure 2. 2024 broiler trial: overall FCR in all five groups
NC: basal diet; PC: avilamycin comparator; SP+CV: algal combination; REO: rosemary oil; PRO: mixed probiotic. Days 1–35; eight replicates of eight birds per group; Table 3 reports common SEM = 0.02.
| Group | Mean (common scale) | FCR ± SEM | Source letters |
|---|---|---|---|
| NC |
|
1.71 ± 0.02 | a |
| PC |
|
1.64 ± 0.02 | ab |
| SP+CV |
|
1.55 ± 0.02 | c |
| REO |
|
1.61 ± 0.02 | bc |
| PRO |
|
1.56 ± 0.02 | c |
Bars start at zero and show means only; variability is tabulated, not drawn as error bars. Groups without a shared letter differ at source p<0.05; shared letters do not establish equivalence. Independent HTML presentation of published numerical facts, without source artwork. Not HYGEM product data.
FCR: g feed/g gain; scale 0–2.0. [1] Source: Table3; days1–35; all5groups. doi:10.1016/j.psj.2024.103971
This demonstrates the performance of a specific mixed formulation under the tested broiler, dietary and management conditions. It does not identify which strain is necessary or compare all commercial probiotics. Algae and essential oils are different materials and should not be counted as additional probiotic studies or evidence of a postbiotic effect.
Another trial: community shifts need not mean greater diversity
Fonseca and colleagues allocated 320 Cobb 500 chicks to 32 cages in a 21-day comparison of a basal diet, a B. subtilis preparation, an essential-oil combination and an antibiotic. They reported better probiotic-group FCR relative to the antibiotic; the overall body-weight comparison did not reach their significance threshold. One significant efficiency endpoint should not become a statement that every production measure improved.[2]
Daily fecal sampling identified treatment-related differences in community composition without a significant treatment effect on alpha diversity. Age also strongly influenced the communities. Better efficiency therefore need not accompany an increase in the number of microbial types, and samples from different ages should not be pooled as a simple product response.[2]
Alpha diversity describes within-sample richness or evenness; beta diversity describes differences between samples. Neither is a direct measure of health or function. Fecal relative abundance also does not independently quantify intestinal cell numbers, metabolic flux or nutrient absorption. A mechanism requires additional links among the intervention, measured metabolites and host function.
| Evidence | Question | Interpretation boundary |
|---|---|---|
| FCR, gain and intake | Did production change? | Separate endpoints, periods and units |
| 16S communities | Did composition differ? | Not direct function or flux |
| Metabolites and host responses | Are functional links supported? | Material-specific comparisons needed |
| Cross-site and cost data | Is adoption reproducible and worthwhile? | No guarantee from one publication |
Variable responses belong in the replacement assessment
El-Fateh and colleagues’2024 AGP–FCR meta-analysis reported high between-study heterogeneity. It evaluated AGPs against controls, not an overall direct equivalence comparison of probiotics with AGPs. The comparator response itself therefore varies across conditions; one average must not become a fixed improvement target for every site.[3]
Studies can differ in broiler breed, diet, health background, duration and preparation. Even the same species name can represent different strains, carriers and formulations. These differences determine whether evidence transfers. Comparing published percentages without matching the material and setting is generally insufficient to establish interchangeability.
Figure 3. How to assess a probiotic replacement claim
→
→
→
→
Editorial research-assessment steps, not a biological mechanism, completed validation or statutory procedure.
Distinguish similarity from demonstrated replacement
Failure to detect a significant difference does not establish equal effects. If the question is whether acceptable performance can be maintained, an acceptable margin and a suitable noninferiority or equivalence design should be defined in advance. If the question is improved FCR, estimate the difference and its uncertainty. Different questions need different interpretations rather than a favorable conclusion selected afterward.
Adoption assessment also needs costs and concurrent management changes. Product, testing and introduction costs should use the same boundary as the comparable production result. Missing information should remain a gap; a literature percentage should not be converted directly into guaranteed returns. International stewardship goals explain the motivation, while material- and setting-specific evidence supports adoption.
| Claim | Evidence required |
|---|---|
| A material outperforms a specified AGP | Direct comparison, difference and uncertainty |
| A strategy maintains acceptable performance | Predefined margin and appropriate noninferiority/equivalence design |
| All probiotics can replace AGPs | Not established by a few different preparations |
| A better microbiome proves efficacy | Define the change and connect it to host function |
Frequently asked questions
Are multistrain products necessarily better?
The two trials examined different materials under different conditions. They were not a direct test of single-strain versus multistrain superiority and cannot rank those categories. A useful comparison still requires clear specifications, a comparator and a primary outcome.
Does improved FCR justify replacing medicines?
Production and veterinary diagnosis or treatment are different questions. These experiments can support evaluation of a nutrition strategy but should not delay needed care. The evidence supports a conditional answer: some probiotic preparations can maintain or improve feed efficiency in defined settings. Their relevance to another product or site requires separate assessment.
References
- [1] Selim S, Abdel-Megeid NS, Alhotan RA, Ebrahim A, Hussein E (2024). Nutraceuticals vs. antibiotic growth promoters: differential impacts on performance, meat quality, blood lipids, cecal microbiota, and organ histomorphology of broiler chicken. Poultry Science 103(9): 103971. doi:10.1016/j.psj.2024.103971
- [2] Fonseca A, Kenney S, Van Syoc E, Bierly S, Dini-Andreote F, Silverman J, Boney J, Ganda E (2024). Investigating antibiotic free feed additives for growth promotion in poultry: effects on performance and microbiota. Poultry Science 103(5): 103604. doi:10.1016/j.psj.2024.103604
- [3] El-Fateh M, Bilal M, Zhao X (2024). Effect of antibiotic growth promoters (AGPs) on feed conversion ratio (FCR) of broiler chickens: A meta-analysis. Poultry Science 103(12): 104472. doi:10.1016/j.psj.2024.104472
Research and education; not evidence of a particular product’s efficacy or field result. Animal diagnosis and treatment require veterinary judgement.














